Physician profile
Lisa A Shepler
NPI 1093945644
$7,019.96
in general payments reported to CMS, 2019-2025
33 companies · $1,333 in 2025
The $1,333 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $854 · 2021: $1,316 · 2022: $1,084 · 2023: $903 · 2024: $1,159 · 2025: $1,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,370 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,370.22 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,812.39 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $943.06 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $659.30 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $504.28 | 2019-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $322.07 | 2023-2025 | |
| Pfizer INC. | $310.00 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $295.55 | 2019-2024 | Januvia, Belsomra, Steglatro |
| Amgen INC. | $291.68 | 2020-2025 | Evenity, Otezla, Repatha |
| Currax Pharmaceuticals LLC | $232.63 | 2022-2023 | Contrave, Onzetra Xsail, Nexletol |
| Glaxosmithkline, LLC. | $217.29 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.14 | 2019-2024 | Jardiance |
| Allergan, INC. | $180.39 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.20 | 2022-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $153.12 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $123.27 | 2019-2025 | Spravato |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $122.54 | 2019-2023 | |
| Exact Sciences Corporation | $91.34 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $66.70 | 2022-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $48.95 | 2025 | Voquezna |
| Eisai INC. | $36.81 | 2019 | |
| Daiichi Sankyo INC. | $35.24 | 2024-2025 | Injectafer |
| Sk Life Science, INC. | $27.70 | 2023 | |
| Hologic Sales and Service, LLC | $24.63 | 2025 | Fluent Fluid Management System, Myosure Tissue Removal Device |
| Novartis Pharmaceuticals Corporation | $20.91 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.48 | 2022 | |
| Sumitomo Pharma America, INC. | $17.77 | 2024 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $16.37 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.91 | 2021 | |
| Axsome Therapeutics, INC. | $15.57 | 2025 | Auvelity |
| Kaleo, INC. | $15.55 | 2024 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $14.88 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.42 | 2022 | |
| Lundbeck LLC | $13.82 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Shepler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.